Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Executed comprehensive non-dilutive agreement with Cell ReadyTM, resulting in an extended financial runway into the fourth quarter of 2025
Appointed Juan Vera, M.D. as President and Chief Executive Officer and Monic Stuart, M.D., MPH, as Chief Medical Officer to spearhead Marker’s restructuring efforts and guide clinical advancement of Marker’s multiTAA-specific T cell technology
Announced encouraging non-clinical data from MT-401 program demonstrating increased anti-tumor activity against an acute myeloid leukemia (AML) cell line after treatment with hypomethylating agents (HMA)
Received $2 million of non-dilutive funding from National Institute of Health (NIH) to support MT-401 program for treatment of patients with AML
Commenced treatment of first patient with lymphoma with MT-601 multiTAA-specific T cell-based therapy in Phase 1 trial following positive non-clinical data announcement
HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results for the second quarter ended June 30, 2023.
“The second quarter of 2023 proved to be a highly beneficial time at Marker from an operational and clinical standpoint, and I am excited by our comprehensive strategic advancements,” commented Dr. Juan F. Vera, the new President and Chief Executive Officer of Marker Therapeutics. “Importantly, we extended our cash runway through 2025 by an agreement with Cell Ready, a newly formed contract development and manufacturing organization (CDMO). In exchange for certain cell manufacturing assets, Cell Ready provided Marker with approximately $19 million in cash and Cell Ready will absorb approximately $11 million of Marker’s overhead expense annually while simultaneously ensuring that Marker’s manufacturing and research and development (R&D) needs will be fully met. As a result, we are now able to aggressively and strategically advance our unique multiTAA-specific T cell therapies toward meaningful clinical milestones.”
Dr. Vera added, “Our R&D work has yielded non-clinical evidence for our multiTAA-specific T cell programs. In May, we reported compelling, non-clinical data for the MT-601 product candidate in lymphoma cells that highlighted the potential merit of multiTAA-specific T cell therapy in patients with CD19-directed CAR T cell refractory lymphoma. Shortly after, the first patient, who has relapsed following multiple therapies, including anti-CD19 CAR T treatment, was treated in our Phase 1, multicenter (“APOLLO”) clinical trial.”
“We also continue to progress the MT-401 program in patients suffering from Acute Myeloid Leukemia (AML). In June, we announced positive, non-clinical, in vitro data that demonstrated enhanced MT-401-induced tumor killing in an AML cell line after standard-of-care treatment with hypomethylating agents (HMA), suggesting a synergistic effect of HMA boosting the anti-tumor response of MT-401,” said Dr. Vera. “As a result of this work, Marker was awarded a $2 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with HMA. On the regulatory front, we reached a significant milestone by receiving Orphan Drug Designation for MT-401 in July from the European Medicines Agency (EMA), which validates the potential therapeutic impact of MT-401 in patients with AML and potentially provides an expedited development pathway.”
“Having made these broad-based advances in the second quarter, the new management team and I believe that Marker’s future has never been brighter. These advances position Marker to unlock significant value. To this end, we are finalizing an updated clinical development plan, which we expect to unveil in the coming months,” concluded Dr. Vera.
Recent Clinical and Operational Highlights:
MT-401 (Acute Myeloid Leukemia)
- Marker reported non-clinical data showing enhanced anti-tumor activity of MT-401 in AML cells following HMA exposure.
- Based on non-clinical data, Marker was awarded a $2 million grant from the NIH SBIR program to support clinical investigation of MT-401 after HMA administration.
- After receiving Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA), Marker was granted ODD from the Committee for Orphan Medicinal Products of the EMA for the treatment of AML patients.
- Marker reported non-clinical proof-of-concept data for MT-401 in an Off-the-Shelf (OTS) setting and provided an update on clinical readiness for the OTS program. The U.S. FDA has cleared the clinical protocol to investigate MT-401 OTS in patients with relapsed AML. Marker has implemented a patient cellular inventory and anticipates the first AML patient to be treated with MT-401 OTS during the first half of 2024.
MT-601 (Lymphoma)
- Marker provided non-clinical data demonstrating the anti-tumor activity of MT-601 in anti-CD19 CAR T resistant lymphoma cells, indicating the potential clinical benefit of MT-601 in patients with CAR T refractory lymphoma.
- Initiation of the Phase 1 APOLLO trial (clinicaltrials.gov Identifier: NCT05798897) for treatment of patients with lymphoma who have relapsed after, or are ineligible for, anti-CD19 CAR T cell therapy. First patient with lymphoma was treated with MT-601 at a 200 million cell dose level and showed no treatment-related adverse events, suggesting a similar favorable safety profile and tolerability of multiTAA-specific T cell products as observed in previous clinical studies.
MT-601 (Pancreatic)
- Investigational New Drug (IND) application cleared by U.S. FDA for multicenter Phase 1 trial of MT-601 in patients with metastatic pancreatic cancer in combination with first-line chemotherapy.
- Clinical advancement will be pending additional financial support from non-dilutive grant activities.
Executive Leadership
- Appointed Juan Vera, M.D., President and Chief Executive Officer and Monic Stuart, M.D., MPH, Chief Medical Officer, whose combined experience will significantly aid Marker in advancing its clinical programs.
Strategic and Financial Partnerships
- On June 26, 2023, Marker completed the previously announced non-dilutive transaction with Cell Ready, under which Cell Ready purchased certain cell manufacturing assets from Marker for approximately $19 million in cash. Marker anticipates that the cost savings from the transaction, including the assumption of facility leases by Cell Ready and the hiring by Cell Ready of over 50 of Marker’s employees in its manufacturing, R&D, quality and regulatory affairs functions, will result in a reduction of Marker’s operating expenses by approximately $11 million annually, and should extend Marker’s cash runway into the fourth quarter of 2025.
- In April 2022, Marker entered into a service agreement with Wilson Wolf Manufacturing Corporation (Wilson Wolf Agreement). Pursuant to the Wilson Wolf Agreement, Marker received an additional $1 million in May 2023 as the work was completed within one year from the onset of the agreement, achieving the agreed milestone.
Second Quarter 2023 Financial Highlights:
- Cash Position: At June 30, 2023, Marker had cash and cash equivalents of $18.1 million.
- R&D Expenses: Research and development expenses from continuing operations were $2.4 million for the quarter ended June 30, 2023, compared to $2.9 million for the quarter ended June 30, 2022.
- G&A Expenses: General and administrative expenses from continuing operations were $2.5 million for the quarter ended June 30, 2023, compared to $3.1 million for the quarter ended June 30, 2022.
- Net Income (Loss): Marker reported net income of $2.5 million for the quarter ended June 30, 2023, compared to a net loss of ($9.2) million for the quarter ended June 30, 2022.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The cell therapy technology Marker has in place is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e., tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer the T cells, Marker believes that its product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
To receive future press releases via email, please visit: HTTPS://WWW.MARKERTHERAPEUTICS.COM/EMAIL-ALERTS.
Forward-Looking Statements
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning Marker’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of our clinical trials of our product candidates; our ability to recognize the benefits of the Cell Ready transaction; anticipated cost savings as a result of the Cell Ready transaction; and our future operating expenses and capital expenditure requirements, including our anticipated cash runway. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in Marker’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. Marker assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.
| Marker Therapeutics, Inc. Condensed Consolidated Balance Sheets (Unaudited) | |||||||
| June 30, | December 31, | ||||||
| 2023 | 2022 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 18,122,086 | $ | 11,782,172 | |||
| Prepaid expenses and deposits | 2,087,462 | 1,849,239 | |||||
| Other receivables | 1,746,100 | 2,402,004 | |||||
| Current assets of discontinued operations | – | 585,840 | |||||
| Total current assets | 21,955,648 | 16,619,255 | |||||
| Non-current assets of discontinued operations | 17,802,929 | ||||||
| Total assets | $ | 21,955,648 | $ | 34,422,184 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable and accrued liabilities | $ | 2,660,616 | $ | 2,521,193 | |||
| Current liabilities of discontinued operations | 260,280 | 5,260,616 | |||||
| Total current liabilities | 2,920,896 | 7,781,809 | |||||
| Non-current liabilities of discontinued operations | – | 7,039,338 | |||||
| Total liabilities | 2,920,896 | 14,821,147 | |||||
| Stockholders’ equity: | |||||||
| Preferred stock – $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | – | – | |||||
| Common stock, $0.001 par value, 30 million shares authorized, 8.8 million and 8.4 million shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 8,799 | 8,406 | |||||
| Additional paid-in capital | 449,526,789 | 447,641,680 | |||||
| Accumulated deficit | (430,500,836 | ) | (428,049,049 | ) | |||
| Total stockholders’ equity | 19,034,752 | 19,601,037 | |||||
| Total liabilities and stockholders’ equity | $ | 21,955,648 | $ | 34,422,184 | |||
| Marker Therapeutics, Inc. Condensed Consolidated Statements of Operations (Unaudited) | |||||||||||||||
| For the Three Months Ended | For the Six Months Ended | ||||||||||||||
| June 30, | June 30, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Revenues: | |||||||||||||||
| Grant income | $ | 762,658 | $ | 790,508 | $ | 1,996,995 | $ | 1,754,830 | |||||||
| Total revenues | 762,658 | 790,508 | 1,996,995 | 1,754,830 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 2,377,993 | 2,923,877 | 5,754,492 | 6,194,241 | |||||||||||
| General and administrative | 2,518,725 | 3,135,168 | 4,686,044 | 6,486,465 | |||||||||||
| Total operating expenses | 4,896,718 | 6,059,045 | 10,440,536 | 12,680,706 | |||||||||||
| Loss from operations | (4,134,060 | ) | (5,268,537 | ) | (8,443,541 | ) | (10,925,876 | ) | |||||||
| Other income (expenses): | |||||||||||||||
| Arbitration settlement | – | – | – | (118,880 | ) | ||||||||||
| Interest income | 35,080 | 35,786 | 119,734 | 38,902 | |||||||||||
| Loss from continuing operations | (4,098,980 | ) | (5,232,751 | ) | (8,323,807 | ) | (11,005,854 | ) | |||||||
| Discontinued operations: | |||||||||||||||
| Loss from discontinued operations before income taxes | (2,179,657 | ) | (4,011,437 | ) | (2,922,406 | ) | (8,148,842 | ) | |||||||
| Gain on disposal of discontinued operations | 8,794,426 | – | 8,794,426 | – | |||||||||||
| Income (loss) from discontinued operations | 6,614,769 | (4,011,437 | ) | 5,872,020 | (8,148,842 | ) | |||||||||
| Net income (loss) | $ | 2,515,789 | $ | (9,244,188 | ) | $ | (2,451,787 | ) | $ | (19,154,696 | ) | ||||
| Net earnings (loss) per share, basic and diluted: | |||||||||||||||
| Loss from continuing operations | $ | (0.47 | ) | $ | (0.63 | ) | $ | (0.95 | ) | $ | (1.32 | ) | |||
| Income (loss) from discontinued operations | $ | 0.75 | $ | (0.48 | ) | $ | 0.67 | $ | (0.98 | ) | |||||
| Net earnings (loss) per share | $ | 0.29 | $ | (1.11 | ) | $ | (0.28 | ) | $ | (2.30 | ) | ||||
| Weighted average number of common shares outstanding, | |||||||||||||||
| Basic and diluted | 8,798,956 | 8,359,205 | 8,760,209 | 8,335,119 | |||||||||||
| Marker Therapeutics, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) | |||||||
| For the Six Months Ended | |||||||
| June 30, | |||||||
| 2023 | 2022 | ||||||
| Cash Flows from Operating Activities: | |||||||
| Net loss | $ | (2,451,787 | ) | $ | (19,154,696 | ) | |
| Less: gain (loss) from discontinued operations, net of tax | 5,872,020 | (8,148,842 | ) | ||||
| Net loss from continuing operations | (8,323,807 | ) | (11,005,854 | ) | |||
| Reconciliation of net loss to net cash used in operating activities: | |||||||
| Stock-based compensation | 539,858 | 1,986,402 | |||||
| Changes in operating assets and liabilities: | |||||||
| Prepaid expenses and deposits | (238,223 | ) | (309,254 | ) | |||
| Other receivables | 655,904 | (627,392 | ) | ||||
| Accounts payable and accrued expenses | 197,030 | (1,061,562 | ) | ||||
| Deferred revenue | – | (1,146,186 | ) | ||||
| Net cash used in operating activities – continuing operations | (7,169,238 | ) | (12,163,846 | ) | |||
| Net cash used in operating activities – discontinued operations | (5,775,680 | ) | (856,922 | ) | |||
| Net cash used in operating activities | (12,944,918 | ) | (13,020,768 | ) | |||
| Cash Flows from Investing Activities: | |||||||
| Net cash provided by (used in) investing activities – discontinued operations | 18,664,122 | (4,718,428 | ) | ||||
| Net cash provided by (used in) investing activities | 18,664,122 | (4,718,428 | ) | ||||
| Cash Flows from Financing Activities: | |||||||
| Proceeds from issuance of common stock, net | 619,974 | 63,573 | |||||
| Proceeds from stock options exercise | 736 | – | |||||
| Net cash provided by financing activities | 620,710 | 63,573 | |||||
| Net increase (decrease) in cash, cash equivalents and restricted cash (1) | 6,339,914 | (17,675,623 | ) | ||||
| Cash, cash equivalents and restricted cash at beginning of the period (1) | 11,782,172 | 43,497,331 | |||||
| Cash and cash equivalents at end of the period | $ | 18,122,086 | $ | 25,821,708 | |||
| (1) As of June 30, 2022 and December 31, 2021, the Company had $0 and $1,146,186 of restricted cash, respectively. | |||||||
Contacts
TIBEREND STRATEGIC ADVISORS, INC.
Investors
Daniel Kontoh-Boateng
(862) 213-1398
DBOATENG@TIBEREND.COM
Media
Casey McDonald
(646) 577-8520
CMCDONALD@TIBEREND.COM
